Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Engrail Raises $32 Million From Nan Fung to In-license Neurological Drugs

publication date: Jun 18, 2020

Engrail Therapeutics, a San Diego-area neurological in-licensing company, raised $32 million in a Series A round with all the funds coming from Nan Fung Life Sciences, a subsidiary of Hong Kong property developer Nan Fung Group. Engrail characterized Nan Fung's support as long term, with the parent having made a commitment to invest $1.5 billion in the Fund. So far, Engrail has acquired a modulator of GABA A, a neurotransmitter that is targeted to treat anxiety and epilepsy. Presently available GABA A modulators have side effects and can cause dependence. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital